Key Drivers
- Gross Margin
- Cash Burn
- Rising Leverage
AIAI Summary
TWST is now being valued less as a long-term platform story and more as a near-term operating-leverage test: revenue and gross margin are improving, but investors need to see sustained EBITDA and free-cash-flow progress quickly or the current rerating could fade as cash burn and leverage remain a drag.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Rising Leverage
TWST has solid revenue scale, stable gross margins, and a healthy liquidity cushion, but persistent operating losses, negative free cash flow, and rising leverage mean the investment case still hinges on future profitability rather than current earnings power.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Breakout surge
- •Profit-taking pullback
TWST surged roughly 37% over the last month into a clear short-term uptrend, but the pullback from $102.88 suggests overbought conditions and a possible pause unless it holds the $98.36–$96.65 support zone.
Sharp 37% run-up to $102.88 followed by a brief pullback signals short-term overbought profit-taking
Sentiment & News
Key News Insights:
- •Stock Momentum
- •Insider Sales
- •Revisions Caution
Twist Bioscience rallied sharply on strong volume, but recent insider sales by a director and the chief legal officer may temper enthusiasm around the move.
The stock's upside may be limited near term as bullish price action is offset by notable insider selling and mixed analyst-estimate signals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings